| Website | selectabio.com |
| Category | BioTech |
| Phone | 617-923-1400 |
| Employees | |
| Description | nanoparticle immunomodulatory drugs |
| Total | $102M |
| Series B, 2/09 Polaris Venture Partners Flagship Ventures NanoDimension Timothy A. Springer | $15.1M |
| Series C, 4/10 OrbiMed Advisors Polaris Venture Partners Flagship Ventures NanoDimension Leukon Investments | $15M |
| Grant, 8/10 National Institute on Drug Abuse (NIDA) | $3M |
| Unattributed, 10/11 | $47.3M |
| Series D, 2/12 Rusnano | $22M |
Selecta Biosciences is a biopharmaceutical company developing the first generation of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Our proprietary product platform technology combines recent advances in immunobiology with cutting-edge nanotechnology to develop targeted immunomodulatory nanoparticles.